SRZN
Surrozen Inc
NASDAQ: SRZN · HEALTHCARE · BIOTECHNOLOGY
$31.56
+1.87% today
Updated 2026-04-29
Market cap
$371.23M
P/E ratio
—
P/S ratio
106.77x
EPS (TTM)
$-32.37
Dividend yield
—
52W range
$6 – $34
Volume
0.1M
Surrozen Inc (SRZN) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $12.50M | $12.50M | $10.65M | $3.48M |
| Revenue growth (YoY) | — | — | — | — | +0.0% | -14.8% | -67.4% |
| Cost of revenue | — | $2.93M | $3.30M | $3.27M | $27.23M | $1.44M | $537000.00 |
| Gross profit | — | $-2.93M | $-3.30M | $12.50M | $-27.23M | $10.65M | $2.94M |
| Gross margin | — | — | — | 100.0% | -217.8% | 100.0% | 84.6% |
| R&D | $19.60M | $25.68M | $40.18M | $37.01M | $27.23M | $21.13M | $29.36M |
| SG&A | $5.50M | $7.12M | $14.21M | $19.83M | $15.80M | $15.06M | $16.20M |
| Operating income | $-25.11M | $-32.81M | $-54.39M | $-44.34M | $-45.78M | $-25.54M | $-42.09M |
| Operating margin | — | — | — | -354.7% | -366.2% | -239.7% | -1210.6% |
| EBITDA | $-22.82M | $-31.37M | $-52.33M | $-42.38M | $-41.13M | $-24.10M | $-41.55M |
| EBITDA margin | — | — | — | -339.1% | -329.0% | -226.2% | -1195.1% |
| EBIT | $-25.11M | $-34.30M | $-54.39M | $-44.34M | $-43.04M | $-25.54M | $-42.09M |
| Interest expense | $0.00 | $91000.00 | $2.07M | $1.96M | — | — | — |
| Income tax | — | $-91000.00 | $-2.14M | $-8.34M | $2.75M | $-63.56M | — |
| Effective tax rate | 0.0% | 0.3% | 3.9% | 23.2% | -6.8% | 50.0% | 0.0% |
| Net income | $-24.36M | $-32.63M | $-52.51M | $-27.67M | $-43.04M | $-63.56M | $-242.03M |
| Net income growth (YoY) | — | -33.9% | -61.0% | +47.3% | -55.6% | -47.7% | -280.8% |
| Profit margin | — | — | — | -221.4% | -344.3% | -596.6% | -6960.8% |